TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Core Insights - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on T cell receptor (TCR)-engineered T cell therapies for cancer treatment [3] Group 1: Company Participation - The company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 9:30 a.m. Eastern Time [1] Group 2: Webcast Information - A webcast of the fireside chat will be available on the company's website, with an archived replay accessible for 90 days post-event [2] Group 3: Company Overview - TScan's lead TCR-T therapy candidates are aimed at treating hematologic malignancies to prevent relapse after allogeneic hematopoietic cell transplantation [3] - The company is expanding its ImmunoBank, a repository of therapeutic TCRs for customized multiplex TCR-T therapies targeting various cancers [3] - TScan is currently enrolling patients in both its clinical programs, including the ALLOHA™ Phase 1 heme trial and the PLEXI-T™ Phase 1 solid tumor trial [3]